BioCentury | Jul 1, 2013
Company News

AmideBio sales and marketing update

...AmideBio launched its BioPure Amyloid-beta 1-42 peptide ( beta amyloid 42 ) in laboratory research quantities...
BioCentury | Apr 15, 2013
Company News

ProScript management update

...of project management, quality assurance and regulatory affairs; formerly senior director of regulatory affairs at Biopure Corp....
BioCentury | Jul 27, 2009
Company News

Biopure hematology news

...therapeutic consisting of cross-linked bovine hemoglobin formulated in a balanced salt solution. At April 30, Biopure...
...Division of Corporations on July 7 (see BioCentury, Nov. 3, 2008, & Feb. 23, 2009). Biopure Corp....
BioCentury | Jul 27, 2009
Financial News

Biopure financial update

...delisted on July 28 after filing for protection under Chapter 11 of the Bankruptcy Code. Biopure Corp....
BioCentury | May 25, 2009
Clinical News

Hemopure hemoglobin glutamer: Phase IIb/III hold

...see BioCentury, Dec. 18, 2006). The NMRC submitted a revised protocol to FDA in March. Biopure's...
...injured military personnel on the battlefield, is also on clinical hold (see BioCentury, Jan. 5). Biopure...
...to address vasoactivity, an adverse effect believes to be associated with use of Hemopure alone. Biopure...
BioCentury | Mar 30, 2009
Clinical News

Hemoglobin glutamer: IND resubmitted

...clinical hold on the NMRC's proposed single-blind Phase II Op RESUS trial designed to compare Biopure's...
...brochure (see BioCentury, Jan. 5). Hemopure is approved to treat surgical anemia in South Africa. Biopure Corp....
BioCentury | Mar 23, 2009
Finance

Ebb & Flow

...30 PDUFA date for its PolyHeme solution of polymerized hemoglobin derived from human blood, and Biopure...
BioCentury | Feb 23, 2009
Company News

Biopure hematology news

...or alternative transactions. Last October, South Africa's Medicines Control Council (MCC) withdrew marketing approval of Biopure's...
...a balanced salt solution. At the end of its fiscal year at Oct. 31, 2008, Biopure...
...in cash and a 12-month operating loss of $20.8 million (see BioCentury, Nov. 3, 2008). Biopure Corp....
BioCentury | Jan 5, 2009
Clinical News

Hemoglobin glutamer: IND hold

...Naval Medical Research Center 's proposed single-blind Phase II Op RESUS trial designed to compare Biopure's...
...subject safety, a deficient protocol design, and the content of the investigator brochure. According to Biopure...
...to the hold from the NMRC. Hextend is from Hospira Inc. (NYSE:HSP, Lake Forest, lll.). Biopure Corp....
BioCentury | Nov 3, 2008
Clinical News

Hemopure hemoglobin glutamer regulatory update

...5). The MCC also ordered the stoppage of clinical trials of Hemopure in South Africa. Biopure...
...Phase II trials of the agent had been discontinued in March due to slow enrollment. Biopure...
...an oxygen carrying therapeutic consisting of cross-linked bovine hemoglobin formulated in a balanced salt solution. Biopure Corp....
Items per page:
1 - 10 of 212
BioCentury | Jul 1, 2013
Company News

AmideBio sales and marketing update

...AmideBio launched its BioPure Amyloid-beta 1-42 peptide ( beta amyloid 42 ) in laboratory research quantities...
BioCentury | Apr 15, 2013
Company News

ProScript management update

...of project management, quality assurance and regulatory affairs; formerly senior director of regulatory affairs at Biopure Corp....
BioCentury | Jul 27, 2009
Company News

Biopure hematology news

...therapeutic consisting of cross-linked bovine hemoglobin formulated in a balanced salt solution. At April 30, Biopure...
...Division of Corporations on July 7 (see BioCentury, Nov. 3, 2008, & Feb. 23, 2009). Biopure Corp....
BioCentury | Jul 27, 2009
Financial News

Biopure financial update

...delisted on July 28 after filing for protection under Chapter 11 of the Bankruptcy Code. Biopure Corp....
BioCentury | May 25, 2009
Clinical News

Hemopure hemoglobin glutamer: Phase IIb/III hold

...see BioCentury, Dec. 18, 2006). The NMRC submitted a revised protocol to FDA in March. Biopure's...
...injured military personnel on the battlefield, is also on clinical hold (see BioCentury, Jan. 5). Biopure...
...to address vasoactivity, an adverse effect believes to be associated with use of Hemopure alone. Biopure...
BioCentury | Mar 30, 2009
Clinical News

Hemoglobin glutamer: IND resubmitted

...clinical hold on the NMRC's proposed single-blind Phase II Op RESUS trial designed to compare Biopure's...
...brochure (see BioCentury, Jan. 5). Hemopure is approved to treat surgical anemia in South Africa. Biopure Corp....
BioCentury | Mar 23, 2009
Finance

Ebb & Flow

...30 PDUFA date for its PolyHeme solution of polymerized hemoglobin derived from human blood, and Biopure...
BioCentury | Feb 23, 2009
Company News

Biopure hematology news

...or alternative transactions. Last October, South Africa's Medicines Control Council (MCC) withdrew marketing approval of Biopure's...
...a balanced salt solution. At the end of its fiscal year at Oct. 31, 2008, Biopure...
...in cash and a 12-month operating loss of $20.8 million (see BioCentury, Nov. 3, 2008). Biopure Corp....
BioCentury | Jan 5, 2009
Clinical News

Hemoglobin glutamer: IND hold

...Naval Medical Research Center 's proposed single-blind Phase II Op RESUS trial designed to compare Biopure's...
...subject safety, a deficient protocol design, and the content of the investigator brochure. According to Biopure...
...to the hold from the NMRC. Hextend is from Hospira Inc. (NYSE:HSP, Lake Forest, lll.). Biopure Corp....
BioCentury | Nov 3, 2008
Clinical News

Hemopure hemoglobin glutamer regulatory update

...5). The MCC also ordered the stoppage of clinical trials of Hemopure in South Africa. Biopure...
...Phase II trials of the agent had been discontinued in March due to slow enrollment. Biopure...
...an oxygen carrying therapeutic consisting of cross-linked bovine hemoglobin formulated in a balanced salt solution. Biopure Corp....
Items per page:
1 - 10 of 212